Where to buy entrectinib and where to buy it

Entrectinib is a targeted therapy drug that is a type of receptor tyrosine kinase (RTK) inhibitor. It is mainly used to treat tumors carrying NTRK gene fusion (fusion) or ROS1 gene rearrangement (rearrangement), including recurrent or metastatic conditions.

Entrectinib is now on the market in China and has been included in medical insurance. Patients can purchase it domestically. However, the price is quite expensive, costing about more than 20,000 yuan. For detailed information on specific pricing and Medicare reimbursement, please consult your local hospital pharmacy for accurate guidance. In comparison, the price of foreign generic entrectinib drugs is relatively affordable, especially the generic drugs produced in Laos, which sell for only about one to two thousand yuan. It is worth mentioning that the ingredients of these generic drugs are basically the same as those of the original drugs. However, please consult a professional doctor or pharmacist for advice before purchasing to ensure the safety of the medication.

Enrectinib belongs to the category of multi-target inhibitors and has the ability to act on NTRK and ROS1. Mutations or rearrangements in the NTRK gene and the ROS1 gene are relatively common in some tumors, and entrectinib can target these abnormally active proteins to inhibit tumor growth and spread.

Enrectinib binds to and inhibits the activities of NTRK protein and ROS1 protein, blocking the promotion effect of these proteins on tumor cell proliferation. Abnormal activities of NTRK and ROS1 often lead to uncontrolled growth of tumors, and entrectinib helps restore normal control of these tumors.

Clinical trial results show that entrectinib shows good efficacy in patients with tumors that are positive for NTRK gene fusion or ROS1 gene rearrangement. It significantly extends patient survival and is generally well tolerated. Entrectinib provides an important treatment option for patients for whom conventional treatments are ineffective or intolerable.